Due to fedratinib's significant GI side effect profile and the logistical difficulty of measuring thiamine levels, clinicians should proactively provide patients with thiamine supplements, anti-emetics, and anti-diarrheal therapies. Instructing patients to take the drug with food can also help mitigate GI toxicity.

Clinical trials with zanidatumab revealed significant diarrhea primarily in the first cycle. The successful management strategy involves mandatory loperamide twice daily for the first seven days to improve tolerability and prevent treatment discontinuation, a crucial implementation pearl.

The HORIZON-GEA-01 trial for zanidatumab in gastric cancer mandated prophylactic loperamide (4mg BID) for all patients. This was necessary to manage the high rates of diarrhea (up to 80% of patients), a significant GI toxicity associated with the drug's mechanism of action.

When using the AKT inhibitor capivasertib, preventing rash is more effective than treating it. A recommended strategy for physicians unfamiliar with the drug is to prescribe twice-daily non-drowsy antihistamines proactively for the first 6-8 weeks, as the rash is difficult to manage once it appears.

New targeted therapies like Zanidatamab and Zolbetuximab show great promise but cause significant side effects like diarrhea and nausea. Their successful clinical adoption hinges on proactive management using detailed guidelines and prophylactic medications, as toxicity can be severe enough to force treatment discontinuation despite the drug's efficacy.

For patients sensitive to standard loperamide tablets who experience rebound constipation, the liquid formulation offers more flexible, precise dosing. This allows for better symptom control of diarrhea without overcorrecting and causing constipation, improving overall patient tolerance.

Data from the SOLAR-1 trial showed that adding prophylactic antihistamines for patients taking alpelisib cut the incidence of all-grade rash in half and reduced high-grade rash by 40%. This has become a standard practice for mitigating dermatologic toxicity with this class of drugs.

When patients experience a consistent pattern of diarrhea, clinicians should move from a reactive, per-episode dosing strategy to a proactive, scheduled regimen of loperamide. This provides better control and prevents symptoms from escalating, with the option to de-escalate as the patient stabilizes.

To manage the significant diarrhea associated with the new drug zanidatumab, a proactive approach is critical. The successful HORIZON-GEA trial protocol included mandatory loperamide twice daily for the first seven days of cycle one, a strategy which effectively managed toxicity without leading to treatment discontinuation.